Literature DB >> 2470781

Evidence for multiple human T cell recognition sites on myelin basic protein.

J R Richert1, E D Robinson, G E Deibler, R E Martenson, L J Dragovic, M W Kies.   

Abstract

Myelin basic protein (BP)-specific T cell clones were used to study human T cell recognition sites on the BP molecule. Proliferation assays performed with a panel of xenogeneic BPs of known amino acid sequence and with large peptide fragments of human and guinea pig BPs demonstrated ten different patterns of reactivity. The data provide evidence for at least four different human T cell epitopes within the C-terminal half of the BP molecule, three within the N-terminal half, and three located within the central portion of the molecule. The results indicate that attempts to inhibit anti-BP responses in vivo in an antigen-specific manner will require the suppression of multiple T cell populations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470781     DOI: 10.1016/0165-5728(89)90073-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

1.  Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire.

Authors:  P A Muraro; M Vergelli; M Kalbus; D E Banks; J W Nagle; L R Tranquill; G T Nepom; W E Biddison; H F McFarland; R Martin
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

Review 2.  The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis.

Authors:  K C O'Connor; A Bar-Or; D A Hafler
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.317

3.  Diversity and plasticity of self recognition during the development of multiple sclerosis.

Authors:  V K Tuohy; M Yu; B Weinstock-Guttman; R P Kinkel
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

4.  Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors.

Authors:  M Pette; K Fujita; D Wilkinson; D M Altmann; J Trowsdale; G Giegerich; A Hinkkanen; J T Epplen; L Kappos; H Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

5.  Shifts in the epitopes of myelin basic protein recognized by Lewis rat T cells before, during, and after the induction of experimental autoimmune encephalomyelitis.

Authors:  F Mor; I R Cohen
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

6.  Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones.

Authors:  E Meinl; F Weber; K Drexler; C Morelle; M Ott; G Saruhan-Direskeneli; N Goebels; B Ertl; G Jechart; G Giegerich
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

7.  Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.

Authors:  D Teitelbaum; R Milo; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

8.  Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

Authors:  M Fridkis-Hareli; D Teitelbaum; E Gurevich; I Pecht; C Brautbar; O J Kwon; T Brenner; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

Review 9.  Peptide determinants of myelin proteolipid protein (PLP) in autoimmune demyelinating disease: a review.

Authors:  V K Tuohy
Journal:  Neurochem Res       Date:  1994-08       Impact factor: 3.996

10.  Characterization of measles virus-induced cellular autoimmune reactions against myelin basic protein in Lewis rats.

Authors:  U G Liebert; G A Hashim; V ter Meulen
Journal:  J Neuroimmunol       Date:  1990 Sep-Oct       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.